Cytokinetics Starts Phase 3 Trial of Reldesemtiv in Amyotrophic Lateral Sclerosis

 Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Decline

of SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo

Company Is Planning to Provide Continued Access to Patients Who Complete COURAGE-ALS
and Patients Who Previously Participated in Cytokinetics Sponsored ALS Trials

https://finance.yahoo.com/news/cytokinetics-announces-start-courage-als-113000575.html